Group 1 - The company, Benli Technology (301065.SZ), focuses on the research, production, and sales of pharmaceutical intermediates, pesticide intermediates, and new material intermediates [1] - The current main products in the pharmaceutical intermediate sector are primarily used in the field of quinolone drug intermediates [1] - The company does not have any innovative drug products at present [1]

Group 1 - The acrylic acid concept sector increased by 2.35%, ranking third in terms of growth among concept sectors, with nine stocks rising, including Shenyang Chemical, which hit the daily limit, and Wanhua Chemical, Huayi Group, and Benli Technology, which rose by 8.29%, 7.41%, and 4.28% respectively [1][2] - The main capital inflow into the acrylic acid concept sector was 875 million yuan, with six stocks receiving net inflows, led by Wanhua Chemical with a net inflow of 849 million yuan, followed by Guoen Co., Shenyang Chemical, and Satellite Chemical [2][3] - The net inflow ratios for Guoen Co., Wanhua Chemical, and Shenyang Chemical were 12.53%, 12.32%, and 12.09% respectively, indicating strong investor interest in these stocks [3] Group 2 - The top gainers in the acrylic acid concept sector included Wanhua Chemical, which rose by 8.29%, and Shenyang Chemical, which increased by 10.05%, while Guoen Co. experienced a slight decline of 0.29% [3][4] - The overall performance of the acrylic acid concept sector was positive, contrasting with other sectors such as animal vaccines and avian influenza, which saw declines of 0.96% and 0.90% respectively [2][4] - The trading volume and turnover rates for the leading stocks in the acrylic acid sector were notable, with Wanhua Chemical achieving a turnover rate of 3.77% and Shenyang Chemical at 8.40% [3]

Group 1 - The acrylic acid concept sector declined by 0.80%, ranking among the top declines in the concept sector, with companies like AkzoNobel, Tianlong Group, and Guoen Co. experiencing significant drops [1] - Among the acrylic acid concept stocks, three companies saw price increases, with Baolijia, Bohai Chemical, and Hongqiang Co. rising by 0.60%, 0.46%, and 0.24% respectively [1] - The acrylic acid concept sector experienced a net outflow of 213 million yuan in main funds, with Wanhua Chemical leading the outflow at 145 million yuan [2] Group 2 - The top gainers in the concept sector included rare earth permanent magnets with a rise of 5.64%, while the housing inspection sector fell by 1.47% [2] - The main funds saw inflows into satellite chemicals, Xingye Co., and Shenyang Chemical, with net inflows of 42.6 million yuan, 6.8 million yuan, and 2.6 million yuan respectively [2][3] - The acrylic acid concept stocks with the highest net outflows included Tianlong Group and Huayi Group, with outflows of 63.7 million yuan and 18.8 million yuan respectively [2]

证券代码：301065 证券简称：本立科技 公告编号：2025-023 浙江本立科技股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相关 规定，浙江本立科技股份有限公司（以下简称"公司"或"本公司"）回购专用 证券账户中的股份不参与本次权益分派。公司2024年年度权益分派方案为：以总 股本扣除已回购股份2,847,362股后的103,172,638股为基数，向全体股东每10股 派发现金红利人民币2.00元，实际派发现金红利总额=103,172,638股×2.00元 /10股=20,634,527.60元（含税）。本次权益分派实施后计算除权除息价格时， 按总股本（含回购股份）折算的每10股现金红利（含税）=现金分红总额/总股本 *10=20,634,527.60/106,020,000*10=1.946286元（保留六位小数，最后一位直 接截取，不四舍五入）。本次权益分派实施后除权除息参考价=除权除息日前一 交易日收盘价-按总股本（含回购股份） ...

Group 1 - The acrylic acid concept sector rose by 1.88%, ranking 7th among concept sectors, with 8 stocks increasing in value, including Bohai Chemical which hit the daily limit, and Shuangxiang Co., Shenyang Chemical, and Baolijia showing gains of 4.49%, 2.93%, and 2.59% respectively [1] - The main inflow of funds into the acrylic acid concept sector was 158 million yuan, with Bohai Chemical leading the net inflow at 86.73 million yuan, followed by Wanhua Chemical, Satellite Chemical, and Rike Chemical with net inflows of 71.24 million yuan, 17.03 million yuan, and 11.80 million yuan respectively [2] - In terms of net inflow ratios, Bohai Chemical, Shenyang Chemical, and Rike Chemical had the highest ratios at 14.08%, 5.97%, and 5.93% respectively [3] Group 2 - The top stocks in the acrylic acid concept sector included Bohai Chemical with a daily increase of 10.10% and a turnover rate of 13.09%, while Wanhua Chemical increased by 1.14% with a turnover rate of 0.77% [3][4] - Stocks that experienced declines included Tianlong Group, which fell by 0.98%, and Benli Technology and Acoly, both down by 0.35% [1][4] - The overall performance of the acrylic acid concept sector indicates a positive trend, with significant capital inflows and several stocks showing strong gains [2][3]

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

Group 1 - The legal opinion letter is issued by Allbright Law Offices regarding the cancellation of certain unvested restricted stock granted under Zhejiang Benli Technology Co., Ltd.'s 2024 Restricted Stock Incentive Plan [1][2] - The law firm confirms that the necessary procedures and approvals for the cancellation of the unvested restricted stock have been completed as of the date of the legal opinion [4][6][10] - The company has decided to cancel a total of 96,250 shares of restricted stock that were granted but not vested, due to the departure of two incentive targets and the failure to meet performance targets [8][10] Group 2 - The performance assessment for the first vesting period of the incentive plan was based on revenue and net profit targets, which were not met, resulting in a 0% vesting ratio for the company [8][10] - The company achieved a revenue of 708.83 million yuan and a net profit of 64.57 million yuan in 2024, which did not meet the required performance thresholds for the vesting of the restricted stock [8][10] - The board and the compensation and assessment committee have agreed that the cancellation of the unvested restricted stock complies with relevant laws and regulations, and does not harm the interests of shareholders [10]

Core Viewpoint - Zhejiang Benli Technology Co., Ltd. has announced the cancellation of 962,500 unvested restricted stocks from its 2024 incentive plan due to the departure of two incentive targets and failure to meet performance targets [1][4][7]. Summary by Sections Approval Procedures - The company held multiple board and supervisory meetings to review and approve the incentive plan and its related documents, ensuring compliance with legal and regulatory requirements [2][3][4]. Cancellation Details - The cancellation includes 25,000 shares due to the departure of two incentive targets and 937,500 shares due to the company's failure to meet the performance targets set for the first vesting period [5][7]. Performance Targets - The performance assessment for the first vesting period was based on revenue and net profit targets. The company reported a revenue of 708.83 million yuan and a net profit of 64.57 million yuan for 2024, which did not meet the required thresholds [6][7]. Impact on the Company - The cancellation of the restricted stocks will not materially affect the company's financial status or operational results, nor will it impact the stability of the core team or the continuation of the incentive plan [7][9]. Opinions from Committees - Both the Board's Compensation and Assessment Committee and the Supervisory Committee have agreed that the cancellation process complies with relevant laws and regulations, and does not harm the interests of shareholders [8][9]. Legal Opinion - The legal counsel confirmed that the cancellation of the unvested restricted stocks has followed necessary procedures and obtained required approvals, aligning with applicable laws and the company's regulations [9].

Group 1 - The company held its seventh meeting of the fourth Supervisory Board on May 21, 2025, with all three supervisors present, and the meeting was conducted in accordance with legal and regulatory requirements [1][2]. - The Supervisory Board approved the proposal to use part of the idle raised funds for cash management and entrusted financial management of idle self-owned funds, aiming to enhance fund utilization efficiency and protect shareholder interests [1][2]. - The Supervisory Board also approved the proposal to annul part of the granted but unvested restricted stock from the 2024 incentive plan, confirming that this action complies with relevant laws and regulations and will not adversely affect the company's financial status or shareholder interests [2]. Group 2 - The voting results for both proposals were unanimous, with 3 votes in favor and no votes against or abstaining [2].

作废部分已授予尚未归属的限制性股票相关事项的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江本立科技股份有限公司 2024 年限制性股票激励计划 上海市锦天城律师事务所 关于浙江本立科技股份有限公司 2024 年限制性股票激励计划 作废部分已授予尚未归属的限制性股票相关事项的 法律意见书 致：浙江本立科技股份有限公司 上海市锦天城律师事务所（以下简称"锦天城"或"本所"）接受浙江本立科技 股份有限公司（以下简称"公司"或"本立科技"）的委托，担任公司"2024 年限制 性股票激励计划"（以下简称"本次激励计划"）的法律顾问，根据《中华人民共和 国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证 券法》")、《上市公司股权激励管理办法》(以下简称"《激励管理办法》"或《管 理办法》)、《深圳证券交易所创业板上市公司自律监管指南第1号——业务办理》 （以下简称"《监管指南》"）等有关法律法规的规定，按 ...